• Ihsan Iskesen, Osman Saribulbul, Mustafa Cerrahoglu, Ece Onur, Bugra Destan, and Bekir Hayrettin Sirin.
• Department of Cardiovascular Surgery, Celal Bayar University School of Medicine, Manisa, Turkey. iskesen@yahoo.com
• Heart Surg Forum. 2006 Jan 1; 9 (6): E883-7.

BackgroundCardiac surgery is associated with an inflammatory response that may cause myocardial dysfunction after cardiopulmonary bypass. We examined the efficacy of pentoxifylline to attenuate the cardiopulmonary bypass-induced inflammatory response during heart operations.MethodsIn a prospective, randomized study, 30 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (group P, n = 15) (continuous infusion of 1.5 mg/kg per hour during operation) or not (group C [control], n = 15). Blood samples for measurements of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 were taken from the arterial line in both groups at 5 different time points.ResultsTNF-alpha, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a higher increase in the control group (P < .05).ConclusionsOur results indicate that pentoxifylline infusion during cardiac surgery inhibits the proinflammatory cytokine release caused by cardiopulmonary bypass.

17 keywords...

hide…